microRNAs provide valuable information for cancer and disease diagnosis, treatment, and prognosis. QuarkBio has seen the promising potential of miRNAs for serving as biomarkers in cancer and various diseases, and are continuously working on identifying miRNA biomarkers suitable for patient care. Currently, QuarkBio has multiple miRNA based panel projects in the pipeline.
167 extracellular microRNA biomarkers related to 20+ cancer diseases have been identified by QuarkBio’s big data analytics team. With these targeted biomarkers, researchers in the field of oncology can perform a concise screening of the biomarkers related to the cancer they are researching, using a time-saving and cost-effective method to develop their own panel.
Secondary complications for diabetes patients typically arise after 5 years of living with the disease. Not every diabetes patient will develop secondary complications, but currently there is no way to predict which patient will develop the complications ahead of time for preventive treatment. QuarkBio is looking at microRNA biomarkers that can potentially predict a diabetes patient’s risk of developing secondary complications and also the timeline of when the complications will arise. Currently, we are focused specifically on kidney and retinal complications.